Old Web
English
Sign In
Acemap
>
authorDetail
>
Sarah C. Wilson
Sarah C. Wilson
Cancer research
Pathology
Medicine
Refractory
Growth inhibition
2
Papers
12
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A phase II study of MT-3724, a novel CD20-targeting engineered toxin body, to evaluate safety, pharmacodynamics, and efficacy in subjects with relapsed or refractory diffuse large B-cell lymphoma.
2020
Journal of Clinical Oncology
Adolfo Enrique Diaz Duque
Tetiana Perekhrestenko
Vasile Musteaţă
Mamia Zodelava
Troy H. Guthrie
Thomas Strack
Christine Burnett
Sarah C. Wilson
Roger J. Waltzman
Tara Baetz
Daniel O. Persky
Show All
Source
Cite
Save
Citations (2)
Results of the first-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain (BD) and extra terminal (BET) proteins, in patients (pts) with relapsed/refractory (R/R) solid tumors.
2018
Journal of Clinical Oncology
Sarina Anne Piha-Paul
Jasgit C. Sachdev
Minal Barve
Patricia LoRusso
Russell Z. Szmulewitz
Sapna Pradyuman Patel
Mark D. McKee
Johannes Wolff
Beibei Hu
Anjla Sood
Xiaotian Chen
Sarah C. Wilson
Bert H. O’Neil
Show All
Source
Cite
Save
Citations (10)
1